Continued Negative Operating Cash Flow and Uncertainty over Securing Funds
First written in FY2021. 5 of 15 entries say "Mitigated", first in FY2022-Q1. Latest entry: FY2026.
Perseus Proteomics moved to the "Worse" side of this theme in 2023, 1 year after the typical company in this theme (2022).
The whole theme swung hardest in 2025: 6 of 12 companies on the "Worse" side.
5 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Net cash used in operating activities was ¥653.334 million.」
Negative operating cash flow has continued, but the outflow decreased from ¥719.485 million in the previous fiscal year to ¥653.334 million. - 2026-05-14MitigatedEarnings
「Net cash used in operating activities was ¥653.334 million.」
Operating cash flow remained negative, although cash outflows decreased from ¥719.485 million in the previous fiscal year to ¥653.334 million. Cash and cash equivalents meanwhile decreased by ¥152.574 million. - FY2026-H1MitigatedAnnual report
「Cash flow from operating activities was an outflow of ¥275.623 million.」
Negative operating cash flow has continued, but the outflow decreased from ¥312.460 million in the same period of the previous year to ¥275.623 million. Meanwhile, cash and cash equivalents decreased by ¥282.642 million due to payments for research and development expenses and other items. - FY2025MitigatedAnnual report
「Cash flow from operating activities was an outflow of ¥719.485 million.」
Negative operating cash flow has continued, but the outflow decreased from ¥833.898 million in the previous fiscal year to ¥719.485 million, while cash and cash equivalents increased by ¥126.501 million. - FY2025-H1RestatedAnnual report
「Cash flow from operating activities was an outflow of ¥312.460 million.」
Negative cash flow from operating activities has continued. While expenditures related to research and development and other activities have continued, cash and cash equivalents increased through the exercise of share acquisition rights. - FY2024WorsenedAnnual report
「Cash flow from operating activities was an outflow of ¥833.898 million.」
The outflow from operating activities increased from ¥564.274 million in the previous fiscal year to ¥833.898 million, while cash and cash equivalents also decreased by ¥903.514 million. - FY2024-Q3WorsenedAnnual report
「Total assets at the end of the third quarter decreased by ¥769.986 million from the end of the previous fiscal year to ¥1,796.664 million. This was mainly due to a ¥781.357 million decrease in cash and deposits resulting from payments for research and development expenses and head office relocation costs.」
Cash and deposits decreased by ¥781.357 million from the end of the previous fiscal year due to payments for research and development expenses and head office relocation costs. Cash outflows have expanded as research and development continues. - FY2024-Q2WorsenedAnnual report
「Cash flow from operating activities was an outflow of ¥464.745 million. This was due mainly to an increase from long-term deposits received and other items, including grants from AMED, offset by a decrease resulting from the recognition of a pretax quarterly net loss of ¥632.523 million and other factors.」
The outflow from operating activities was ¥464.745 million, up from ¥255.906 million in the same period of the previous year. Cash and cash equivalents also decreased by ¥578.925 million from the beginning of the period. - FY2024-Q1WorsenedAnnual report
「This was primarily due to a ¥408.510 million decrease in cash and deposits resulting from payments for research and development expenses, relocation costs and other items.」
Cash and deposits at the end of the current quarter decreased by ¥408.510 million from the end of the previous fiscal year due to payments for research and development expenses, relocation costs and other items, with cash outflows continuing. - FY2023WorsenedAnnual report
「Cash flow from operating activities was an outflow of ¥564.274 million.」
Negative operating cash flow has continued, and the outflow increased from ¥476.842 million in the previous fiscal year to ¥564.274 million. - FY2023-Q2RestatedAnnual report
「Cash flow from operating activities was an outflow of ¥255.906 million.」
Negative cash flow from operating activities has continued, and cash outflows associated with research and development expenses and other costs have also continued. - FY2022RestatedAnnual report
「Cash flow from operating activities was an outflow of ¥476.842 million, compared with ¥422.836 million in the previous fiscal year.」
This reconfirms the structure in which negative operating cash flow continues and funding through capital increases and upfront payments and milestones from alliance partners is necessary. - FY2022-Q2RestatedAnnual report
「Cash flow from operating activities was an outflow of ¥205.161 million.」
Negative cash flow from operating activities has continued. Meanwhile, cash and cash equivalents at the end of the period amounted to ¥3,506.229 million. - FY2022-Q1MitigatedAnnual report
「This was primarily attributable to ¥2,641.320 million in cash and deposits raised through a public offering conducted in connection with the listing of the Company's shares on the Mothers market of the Tokyo Stock Exchange.」
The public offering raised ¥2,641.320 million in cash and deposits, changing the Company's funding position. Meanwhile, the Company also recorded an operating loss and net loss in the current quarter. - FY2021First statedAnnual report
「Research-driven companies such as the Company tend to report operating losses continuously during the development period, resulting in negative cash flow from operating activities. As the Company's operating cash flow also remains negative, it intends to secure funding through capital increases as well as upfront payments and milestones from alliance partners in line with the progress of research and development.」
This shows a structural need to secure funding through capital increases and income from alliance partners as negative operating cash flow continues.